Switching to Insulin Degludec from Insulin Glargine U100 Improves Glycemic Control in People with Type 1 (T1D) or Type 2 diabetes (T2D) in a Real-World Setting

被引：2

作者：

Knudsen, Soren T.

Tentolouris, Nikolaos

Schultes, Bernd

Lapolla, Annunziata

Eidenmueller, Markus

Prager, Rudolf

Catarig, Andrei-Mircea

Wolden, Michael L.

Siegmund, Thorsten

机构：

来源：

DIABETES | 2018年 / 67卷

关键词：

D O I：

10.2337/db18-1014-P

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Improved Glycemic Control in People with Type 2 Diabetes (T2D) Initiating or Switching to Insulin Degludec/Insulin Aspart (IDegAsp) in a Real-World Setting in China
Guo, Lixin
Chen, Liming
Zhao, Fan
Liu, Xiao Y.
Ding, Hongcheng
Wang, Kun
Xing, Zhong
Shankarappa, Vinay Babu
Chaudhary, Gaurav
DIABETES, 2024, 73
[2] Insulin Degludec Has Lower Hypoglycemia Risk than Insulin Glargine U100 in Older People with Type 2 Diabetes (T2D)
Heller, Simon R.
Devries, J. Hans
Wysham, Carol H.
Hansen, Charlotte T.
Hansen, Melissa V.
Frier, Brian M.
DIABETES, 2018, 67
[3] Efficacy and Safety of Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in Hispanic Patients with Type 2 Diabetes (T2D)
Chaykin, Louis B.
Bhargava, Anuj
Wysham, Carol H.
Abrahamsen, Trine
Van Leeuwen, Michiel
De la Rosa, Raymond
DIABETES, 2017, 66 : A617 - A617
[4] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D
Sullivan, Sean D.
Bailey, Timothy S.
Roussel, Ronan
Zhou, Fang L.
Bosnyak, Zsolt
Preblick, Ron
Westerbacka, Jukka
Gupta, Rishab
Blonde, Lawrence
DIABETES, 2018, 67
[5] Converting to Insulin Degludec/Liraglutide (IDegLira) Is Efficacious Regardless of Pretrial Insulin Dose in Patients with Type 2 Diabetes (T2D) Uncontrolled on Insulin Glargine U100 (IGlar)
Meneghini, Luigi F.
Jaeckel, Elmar
Leiter, Lawrence A.
Lingvay, Ildiko
Harvey, John N.
Begtrup, Kamilla
Chandarana, Keval
Vilsboll, Tina
DIABETES, 2017, 66 : A289 - A289
[6] REAL-WORLD EVIDENCE DEMONSTRATES COMPARABLE CLINICAL OUTCOMES OF SWITCHING FROM INSULIN GLARGINE 100 U/ML TO INSULIN GLARGINE 300 U/ML VS INSULIN DEGLUDEC IN T2D PATIENTS
Blonde, L.
Zhou, F. L.
Bosnyak, Z.
Westerbacka, J.
Gupta, V. E.
Sharma, R. K.
Bailey, T. S.
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A137 - A138
[7] Switching to Insulin Degludec Improves Glycemic Control in Patients with T2DM in a Real-World Setting
Schultes, Bernd
Tentolouris, Nikolaos
Knudsen, Soren T.
Lapolla, Annunziata
Eidenmueller, Markus
Prager, Rudolf
Phan, Tra-Mi
Wolden, Michael L.
Siegmund, Thorsten
DIABETES, 2017, 66 : A266 - A266
[8] Real-World Health Outcomes of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Glargine 100 U/mL (Gla-100) in Patients with Type 1 (T1D) and Type 2 Diabetes (T2D) in the Canadian LMC Diabetes Patient Registry-The REALITY Study
Abitbol, Alexander
Brown, Ruth E.
Jiandani, Dishay
Sauriol, Luc
Aronson, Ronnie
DIABETES, 2018, 67
[9] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D plus Subgroup Analyses
Sullivan, Sean D.
Bailey, Timothy S.
Roussel, Ronan
Zhou, Fang L.
Bosnyak, Zsolt
Preblick, Ron
Westerbacka, Jukka
Gupta, Rishab
Blonde, Lawrence
DIABETES, 2018, 67
[10] Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
Evans, Marc
Mehta, Roopa
Gundgaard, Jens
Chubb, Barrie
DIABETES THERAPY, 2018, 9 (05) : 1919 - 1930

← 1 2 3 4 5 →